-
公开(公告)号：US20150065522A1
公开(公告)日：2015-03-05
申请号：US14477566
申请日：2014-09-04
发明人： Brian K. Albrecht , Steven F. Bellon , Victor S. Gehling , Jean-Christophe Harmange , Yves LeBlanc , Jun Liang , Steven Magnuson , Vicki Tsui , Birong Zhang
IPC分类号： C07D487/04 , A61K45/06 , A61N5/10 , A61K31/519
CPC分类号： C07D487/04 , A61K31/519 , A61K45/06 , A61N5/10
摘要： The present invention relates to compounds formula (I): and to salts thereof, wherein R1-R4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.
摘要翻译： 本发明涉及式（I）化合物及其盐，其中R 1 -R 4和A具有说明书中定义的任何值及其组成和用途。 该化合物可用作组蛋白脱甲基酶的抑制剂，例如KDM5。 还包括包含本发明化合物的药学上可接受的组合物和使用所述组合物治疗各种疾病的方法。
-
公开(公告)号：US10308614B2
公开(公告)日：2019-06-04
申请号：US15686028
申请日：2017-08-24
发明人： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven R. Magnuson , Christopher G. Nasveschuk , F. Anthony Romero , Yong Tang , Alexander M. Taylor
IPC分类号： C07D237/20 , C07D401/04 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D413/04 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/08 , C07D498/10 , A61K31/50 , A61K31/51 , C07D401/12 , C07D237/22 , C07D417/14 , C07D413/12 , C07D451/02 , C07D487/04 , A61K45/06 , A61K31/337 , A61K31/437 , A61K31/501
摘要： The present invention relates to compounds of formula (I): and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.
-
公开(公告)号：US10206931B2
公开(公告)日：2019-02-19
申请号：US15482581
申请日：2017-04-07
发明人： F. Anthony Romero , Steven R. Magnuson , Richard Pastor , Vickie Hsiao-Wei Tsui , Jeremy Murray , Terry Crawford , Daniel J. Burdick , Brian K. Albrecht , Alexandre Cote , Alexander M. Taylor , Christopher G. Nasveschuck , Yves LeBlanc , Michael Charles Hewitt , Kwong Wah Lai , Kevin Chen
IPC分类号： A61K31/551 , C07D243/12 , C07D403/04 , C07D403/14 , A61K31/55 , C07D223/16 , C07D267/14 , C07D401/14 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/04 , C07D405/12 , C07D413/04 , C07D413/10 , C07D243/24 , C07D471/04 , C07D495/04 , A61K45/06 , A61K31/337 , A61K31/5513
摘要： The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
公开(公告)号：US20180009735A1
公开(公告)日：2018-01-11
申请号：US15658219
申请日：2017-07-24
发明人： Brian K. Albrecht , James Edmund Audia , Alexandre Cote , Martin Duplessis , Victor S. Gehling , Andrew Charles Good , Jean-Christophe Harmange , Yves LeBlanc , Christopher G. Nasveschuk , Alexander M. Taylor , Rishi G. Vaswani
IPC分类号： C07C211/42 , C07D401/12 , A61K31/135 , A61K31/166 , C07D309/04 , C07D305/08 , C07D295/185 , C07D231/12 , C07D215/08 , C07D213/38 , C07D211/46 , C07D211/26 , C07D207/06 , C07D205/12 , C07D205/04 , C07C317/36 , C07C255/58 , C07C237/48 , C07C229/50 , C07C217/74 , A61K45/06 , A61K31/517 , A61K31/495 , A61K31/4747 , A61K31/4545 , A61K31/445 , A61K31/4406 , A61K31/437 , A61K31/4155 , A61K31/415 , A61K31/40 , A61K31/397 , A61K31/351 , A61K31/337 , A61K31/277 , A61K31/196 , C07D405/12
CPC分类号： C07C211/42 , A61K31/135 , A61K31/166 , A61K31/196 , A61K31/277 , A61K31/337 , A61K31/351 , A61K31/397 , A61K31/40 , A61K31/415 , A61K31/4155 , A61K31/437 , A61K31/4406 , A61K31/445 , A61K31/4545 , A61K31/4747 , A61K31/495 , A61K31/517 , A61K45/06 , C07C217/74 , C07C229/50 , C07C237/48 , C07C255/58 , C07C317/36 , C07C2601/02 , C07C2601/04 , C07C2603/94 , C07D205/04 , C07D205/12 , C07D207/06 , C07D211/26 , C07D211/46 , C07D211/78 , C07D213/38 , C07D215/08 , C07D231/12 , C07D295/185 , C07D305/08 , C07D309/04 , C07D401/12 , C07D405/12
摘要： Provided herein are compounds of formula I: and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various LSD1-mediated disorders.
-
公开(公告)号：US20170340604A1
公开(公告)日：2017-11-30
申请号：US15592012
申请日：2017-05-10
发明人： Brian K. Albrecht , Steven F. Bellon , Daniel J. Burdick , Alexandre Cote , Terry Crawford , Les A. Dakin , Vickie Hsiao-Wei Tsui , Michael Charles Hewitt , Yves LeBlanc , Steven R. Magnuson , Christopher G. Nasveschuk , Anthony F. Romero , Yong Tang , Alexander M. Taylor , Shumei Wang
IPC分类号： A61K31/40 , C07D471/04
CPC分类号： A61K31/40 , C07D471/04 , C07D519/00
摘要： The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.
-
公开(公告)号：US10316023B2
公开(公告)日：2019-06-11
申请号：US15449706
申请日：2017-03-03
发明人： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven Magnuson , Christopher G. Nasveschuk , Richard Pastor , F. Anthony Romero , Alexander M. Taylor
IPC分类号： C07D249/12 , C07D403/04 , C07D403/12 , C07D401/04 , C07D401/12 , A61K31/53 , A61K31/4196 , A61P35/00 , C07D253/075 , A61K45/06
摘要： The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20180086720A1
公开(公告)日：2018-03-29
申请号：US15686028
申请日：2017-08-24
发明人： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven R. Magnuson , Christopher G. Nasveschuk , Anthony F. Romero , Yong Tang , Alexander M. Taylor
IPC分类号： C07D237/20 , C07D401/12 , C07D401/04 , C07D487/04 , C07D403/04 , C07D487/08 , C07D498/10 , C07D471/10 , C07D403/14 , C07D413/12 , C07D403/12 , C07D413/14 , C07D405/14 , C07D417/14 , C07D237/22 , C07D451/02 , C07D413/04
CPC分类号： C07D237/20 , A61K31/337 , A61K31/437 , A61K31/501 , A61K45/06 , C07D237/22 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/14 , C07D451/02 , C07D471/10 , C07D487/04 , C07D487/08 , C07D498/10 , A61K2300/00
摘要： The present invention relates to compounds of formula (I): and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.
-
公开(公告)号：US20170312292A1
公开(公告)日：2017-11-02
申请号：US15482581
申请日：2017-04-07
发明人： Anthony F. Romero , Steven R. Magnuson , Richard Pastor , Vickie Hsiao-Wei Tsui , Jeremy Murray , Terry Crawford , Daniel J. Burdick , Brian K. Albrecht , Alexandre Cote , Alexander M. Taylor , Christopher G. Nasveschuck , Yves LeBlanc , Michael Charles Hewitt , Kwong Wah Lai , Kevin Chen
IPC分类号： A61K31/55 , C07D403/04 , C07D243/24 , A61K31/5513 , C07D243/12 , C07D223/16 , C07D403/14 , C07D267/14
CPC分类号： A61K31/55 , A61K31/337 , A61K31/5513 , A61K45/06 , C07D223/16 , C07D243/12 , C07D243/24 , C07D267/14 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/14 , C07D405/04 , C07D405/12 , C07D413/04 , C07D413/10 , C07D471/04 , C07D495/04 , A61K2300/00
摘要： The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
公开(公告)号：US20170275289A1
公开(公告)日：2017-09-28
申请号：US15449692
申请日：2017-03-03
发明人： Brian K. Albrecht , Alexandre Cote , Terry Crawford , Martin Duplessis , Andrew Charles Good , Yves LeBlanc , Steven Magnuson , Christopher G. Nasveschuk , Richard Pastor , Anthony F. Romero , Alexander M. Taylor
IPC分类号： C07D487/04 , A61K31/5025 , C07D237/34 , A61K31/502 , A61K31/5377 , C07D403/12 , C07D401/12 , A61K31/55 , C07D405/12 , C07D471/04 , C07D237/32
CPC分类号： C07D487/04 , A61K31/502 , A61K31/5025 , A61K31/5377 , A61K31/55 , C07D237/32 , C07D237/34 , C07D401/12 , C07D403/12 , C07D405/12 , C07D471/04
摘要： The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.043 秒)
